Karolyn Morris

464 total citations
9 papers, 259 citations indexed

About

Karolyn Morris is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, Karolyn Morris has authored 9 papers receiving a total of 259 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pathology and Forensic Medicine, 5 papers in Genetics and 4 papers in Oncology. Recurrent topics in Karolyn Morris's work include Lymphoma Diagnosis and Treatment (7 papers), Chronic Lymphocytic Leukemia Research (4 papers) and CAR-T cell therapy research (3 papers). Karolyn Morris is often cited by papers focused on Lymphoma Diagnosis and Treatment (7 papers), Chronic Lymphocytic Leukemia Research (4 papers) and CAR-T cell therapy research (3 papers). Karolyn Morris collaborates with scholars based in United States, United Kingdom and South Africa. Karolyn Morris's co-authors include Christopher Janus, I T Magrath, Robert J. Spiegel, CW Berard, Ryan C. Lynch, Daniel Crooks, Ajay K. Gopal, Ryan D. Cassaday, Heather Rasmussen and Jenna Voutsinas and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal of Thoracic Oncology.

In The Last Decade

Karolyn Morris

9 papers receiving 241 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Karolyn Morris United States 4 190 120 99 83 61 9 259
Olga García Spain 12 209 1.1× 170 1.4× 105 1.1× 102 1.2× 58 1.0× 24 318
Gottfried Doelken Germany 8 179 0.9× 174 1.4× 77 0.8× 68 0.8× 28 0.5× 15 296
Y. Ishigatsubo Japan 6 158 0.8× 124 1.0× 54 0.5× 100 1.2× 19 0.3× 21 303
Musa Alzahrani Saudi Arabia 8 169 0.9× 112 0.9× 81 0.8× 40 0.5× 11 0.2× 41 259
Francesco Volzone Italy 8 140 0.7× 98 0.8× 48 0.5× 54 0.7× 36 0.6× 17 260
S. Nakashima Japan 9 81 0.4× 64 0.5× 50 0.5× 50 0.6× 35 0.6× 49 256
Stephen D. Anesi United States 11 62 0.3× 117 1.0× 35 0.4× 73 0.9× 37 0.6× 37 514
Concepción Nicolás Spain 6 102 0.5× 42 0.3× 112 1.1× 93 1.1× 39 0.6× 10 191
Dennis Slater United States 5 81 0.4× 53 0.4× 28 0.3× 35 0.4× 31 0.5× 15 178
Neel K. Gupta United States 6 173 0.9× 90 0.8× 152 1.5× 97 1.2× 15 0.2× 17 247

Countries citing papers authored by Karolyn Morris

Since Specialization
Citations

This map shows the geographic impact of Karolyn Morris's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karolyn Morris with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karolyn Morris more than expected).

Fields of papers citing papers by Karolyn Morris

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karolyn Morris. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karolyn Morris. The network helps show where Karolyn Morris may publish in the future.

Co-authorship network of co-authors of Karolyn Morris

This figure shows the co-authorship network connecting the top 25 collaborators of Karolyn Morris. A scholar is included among the top collaborators of Karolyn Morris based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karolyn Morris. Karolyn Morris is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

9 of 9 papers shown
1.
Lynch, Ryan C., Ryan D. Cassaday, Stephen D. Smith, et al.. (2024). Dose-Dense Brentuximab Vedotin Plus Ifosfamide, Carboplatin, and Etoposide (ICE) in Second Line Treatment of Relapsed/Refractory Classical Hodgkin Lymphoma: 5-Year Long Term Follow up. Blood. 144(Supplement 1). 3043–3043. 1 indexed citations
2.
Lynch, Ryan C., Christina Poh, Chaitra S. Ujjani, et al.. (2022). Polatuzumab vedotin with dose-adjusted etoposide, cyclophosphamide, doxorubicin, and rituximab (Pola-DA-EPCH-R) for upfront treatment of aggressive B-cell non-Hodgkin lymphomas.. Journal of Clinical Oncology. 40(16_suppl). 7546–7546. 1 indexed citations
3.
Lynch, Ryan C., Ryan D. Cassaday, Stephen D. Smith, et al.. (2021). Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study. The Lancet Haematology. 8(8). e562–e571. 33 indexed citations
4.
Graf, Solomon A., Ryan D. Cassaday, Karolyn Morris, et al.. (2020). Ibrutinib Monotherapy in Relapsed or Refractory, Transformed Diffuse Large B-cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 21(3). 176–181. 10 indexed citations
5.
Graf, Solomon A., Ryan D. Cassaday, Karolyn Morris, et al.. (2019). Ibrutinib in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma: Final Results from a Prospective Phase II Study. Blood. 134(Supplement_1). 1596–1596. 2 indexed citations
6.
Graf, Solomon A., Ryan D. Cassaday, Karolyn Morris, et al.. (2018). Ibrutinib Is Effective in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma: Results from a Prospective Phase II Study. Blood. 132(Supplement 1). 2954–2954. 1 indexed citations
7.
Lisberg, Aaron, D. Andrew Tucker, Jonathan W. Goldman, et al.. (2017). P3.02c-083 Treatment Related Adverse Events Predict Improved Clinical Outcome in NSCLC Patients on KEYNOTE-001 at a Single Center. Journal of Thoracic Oncology. 12(1). S1328–S1328. 1 indexed citations
8.
Bhattacharyya, Debasish, et al.. (2003). B cell non-Hodgkin cerebral lymphoma associated with an anaplastic oligodendroglioma.. PubMed. 21(6). 243–7. 10 indexed citations
9.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Olga García Breakdown of academic impact, for papers by Gottfried Doelken Breakdown of academic impact, for papers by Y. Ishigatsubo Breakdown of academic impact, for papers by Musa Alzahrani Breakdown of academic impact, for papers by Francesco Volzone Breakdown of academic impact, for papers by S. Nakashima Breakdown of academic impact, for papers by Stephen D. Anesi Breakdown of academic impact, for papers by Concepción Nicolás Breakdown of academic impact, for papers by Dennis Slater Breakdown of academic impact, for papers by Neel K. Gupta
Rankless by CCL
2026